Treatment Response to Xiaflex for Men With Peyronie's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-09-02

Study Completion Date

2021-07-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to develop a database of patients with Peyronie's disease who are treated at the University of Miami. The collected data will help the researchers to better understand Peyronie's disease and its response to therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response

NCT03767452

Peyronie's Disease

UNKNOWN PHASE4

Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's

NCT04786106

Peyronie's Disease

ACTIVE_NOT_RECRUITING PHASE4

Medical Treatment of Peyronie's Disease With Collagenase Clostridium Histolyticum

NCT04370652

Peyronie Disease

COMPLETED

Xiaflex® Plus Testosterone Treatment Pilot Study Protocol

NCT03815331

Peyronie's Disease (PD)

COMPLETED PHASE4

Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease

NCT06065436

Peyronie Disease Erectile Dysfunction

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peyronie Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Xiaflex group

Patients will be evaluated in our urology clinic at baseline for possible inclusion in our study. All patients at baseline evaluation will be evaluated for duration of symptoms, relationship stability, IIEF and PDQ. All patients will obtain a penile Doppler ultrasound with the aid of a vasoactive substance by a specially trained technician. During this visit, plaque measurements will be taken: location of plaque, distance of plaque from the tip of the penis, degree of curvature measured by goniometer.

Ultrasound characteristics will be documented: Type (Type 1: The plaque appears as a thickening of the tunica albuginea without acoustic shadowing. Type 2: A moderately calcified plaque with a typical ultrasound shadow. Type 3: A severely calcified plaque with typical ultrasound shadowing) and Grade of calcification (grade 1 (\<0.3 cm), grade 2 (\>0.3 cm, \<1.5 cm), grade 3 (\>1.5 cm; or ≥ 2 plaques \>1.0 cm). Sample data sheet attached as appendix 2.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years
* Able to provide informed consent
* A stable relationship for ≥3 months
* PD symptoms with evidence of stable disease as determined by the investigator
* Penile curvature deformity of \>30° to \<90°
* Has not had previous surgery for PD
* Has not had previous therapy with Xiaflex for PD

Exclusion Criteria

* Ventral plaque
* Active phase PD
* Actively on anticoagulation during time frame of injections
* Aspirin 81mg will be eligible for therapy
* Hour glass deformity
* Previous allergic reaction to Xiaflex
* Unwilling to participate
* Medically unfit for sexual intercourse as deemed by the principal investigator
* Patients scheduled to undergo an elective medical procedure during the investigation timeframe that will interfere with Xiaflex injection cycles as deemed by the PI

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No